Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more
Sinil Pharmaceutical Co. Ltd (012790) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.017x
Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has a cash flow conversion efficiency ratio of 0.017x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.62 Billion) by net assets (₩151.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinil Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sinil Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ilji Technology Co. Ltd
KQ:019540
|
0.067x |
|
Tplex Co. Ltd
KQ:081150
|
0.005x |
|
Cyberfuels Holding Company Inc.
PINK:CBRF
|
-0.028x |
|
PharmaCorp Rx Inc.
V:PCRX
|
0.018x |
|
Kamdhenu Limited
NSE:KAMDHENU
|
0.039x |
|
DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen
XETRA:DAM
|
-0.026x |
|
Midway Limited
F:MI6
|
-0.022x |
|
DGL Group Ltd
AU:DGL
|
0.078x |
Annual Cash Flow Conversion Efficiency for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Sinil Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩146.51 Billion | ₩22.69 Billion | 0.155x | +37.85% |
| 2023-12-31 | ₩134.90 Billion | ₩15.15 Billion | 0.112x | +1.18% |
| 2022-12-31 | ₩123.28 Billion | ₩13.69 Billion | 0.111x | +12.59% |
| 2021-12-31 | ₩113.20 Billion | ₩11.16 Billion | 0.099x | -4.18% |
| 2020-12-31 | ₩107.48 Billion | ₩11.06 Billion | 0.103x | -15.33% |
| 2019-12-31 | ₩101.24 Billion | ₩12.31 Billion | 0.122x | +25.83% |
| 2018-12-31 | ₩95.18 Billion | ₩9.19 Billion | 0.097x | +1.27% |
| 2017-12-31 | ₩90.93 Billion | ₩8.67 Billion | 0.095x | -31.23% |
| 2016-12-31 | ₩87.19 Billion | ₩12.09 Billion | 0.139x | +13.38% |
| 2015-12-31 | ₩78.17 Billion | ₩9.56 Billion | 0.122x | -7.08% |
| 2014-12-31 | ₩70.85 Billion | ₩9.33 Billion | 0.132x | -- |